Supernus Pharmaceuticals Shares Outstanding 2011-2018 | SUPN

Supernus Pharmaceuticals shares outstanding history from 2011 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Supernus Pharmaceuticals shares outstanding for the quarter ending June 30, 2018 were 0.054B, a 1.84% increase year-over-year.
  • Supernus Pharmaceuticals 2017 shares outstanding were 0.053B, a 3.08% increase from 2016.
  • Supernus Pharmaceuticals 2016 shares outstanding were 0.052B, a 1.07% increase from 2015.
  • Supernus Pharmaceuticals 2015 shares outstanding were 0.051B, a 21.06% increase from 2014.
Supernus Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2017 53
2016 52
2015 51
2014 42
2013 32
2012 17
2011 2
2010 2
Supernus Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 54
Q1 2018 54
Q4 2017 53
Q3 2017 54
Q2 2017 53
Q1 2017 53
Q4 2016 52
Q3 2016 52
Q2 2016 52
Q1 2016 51
Q4 2015 51
Q3 2015 52
Q2 2015 52
Q1 2015 45
Q4 2014 42
Q3 2014 43
Q2 2014 42
Q1 2014 41
Q4 2013 32
Q3 2013 31
Q2 2013 31
Q1 2013 31
Q4 2012 17
Q3 2012 24
Q2 2012 17
Q1 2012 2
Q4 2011 2
Q3 2011 2
Q2 2011 2
Q1 2011 2
Q4 2010 0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.517B $0.302B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $64.335B 11.04
Teva Pharmaceutical Industries (TEVA) Israel $21.792B 6.09
Mylan (MYL) United Kingdom $16.606B 7.06
Bausch Health Cos (BHC) Canada $8.483B 6.32
Dr Reddy's Laboratories (RDY) India $5.756B 25.71
Mallinckrodt Public (MNK) United Kingdom $2.287B 3.89
Akorn (AKRX) United States $0.882B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.857B 123.53
Homology Medicines (FIXX) United States $0.747B 0.00
CymaBay Therapeutics (CBAY) United States $0.615B 0.00
Assembly Biosciences (ASMB) United States $0.594B 0.00
Voyager Therapeutics (VYGR) United States $0.498B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.485B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.482B 0.00
Corium (CORI) United States $0.454B 0.00
Teligent (TLGT) United States $0.185B 0.00
Sol-Gel Technologies (SLGL) Israel $0.125B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.120B 0.00
Aevi Genomic Medicine (GNMX) United States $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
China Pharma Holdings (CPHI) China $0.019B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00